Oral composition

Abstract

To provide means that can suppress a rise in viscosity of an oral composition containing a thickener, aluminium lactate, and silica even if it is stored.SOLUTION: The present disclosure provides an oral composition containing a thickener, aluminium lactate, silica and hydroxy apatite particles.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present disclosure relates to oral compositions and the like, and more particularly to oral compositions and the like containing aluminum lactate and silica. [Background technology]

[0002] Aluminum lactate is a medicinal ingredient for preventing tooth hypersensitivity, and is therefore incorporated into oral compositions in the hope of achieving this effect. Silica is also incorporated into oral compositions as a tooth abrasive, etc. [Prior art documents] [Patent documents]

[0003] [Patent Document 1] Japanese Patent Application Publication No. 5-155745 Summary of the Invention [Problem to be solved by the invention]

[0004] The present inventors have found that an oral composition containing a thickener, aluminum lactate, and silica increases significantly in viscosity when stored (particularly at relatively high temperatures, for example, about 40 to 60°C). This temperature range is quite acceptable during the distribution of oral composition products (particularly during summer), and from the perspective of maintaining consistent product quality, such an increase in viscosity over time during transportation or storage is undesirable. [Means for solving the problem]

[0005] Therefore, the present inventors investigated a method for suppressing the increase in viscosity over time of an oral composition containing a thickener, aluminum lactate, and silica. As a result, they found that the increase in viscosity (especially the increase in viscosity over time) of the oral composition could be efficiently suppressed by further blending hydroxyapatite particles into the oral composition. Based on this finding, they then conducted further investigations.

[0006] The present disclosure encompasses, for example, the subject matter described in the following sections: Section 1. An oral composition comprising a thickener, aluminum lactate, silica, and hydroxyapatite particles. Section 2. Item 2. The oral composition according to Item 1, wherein the thickener is at least one selected from the group consisting of alginic acid or a salt thereof, hydroxyalkyl cellulose, carboxyalkyl cellulose or a salt thereof, xanthan gum, and carrageenan. Section 3. Item 2. The oral composition according to Item 1, wherein the thickener is carboxymethylcellulose or a salt thereof. Section 4. Item 4. The oral composition according to any one of Items 1 to 3, having a viscosity at 30°C of 400 Pa·s or less. Section A. A method for suppressing an increase in viscosity over time of an oral composition containing a thickener, aluminum lactate, and silica, the method comprising further blending hydroxyapatite particles in the oral composition. [Effects of the Invention]

[0007] An oral composition is provided which contains a thickener, aluminum lactate, and silica and is inhibited from increasing in viscosity during storage. [Brief explanation of the drawings]

[0008] [Figure 1] This is a graph showing the values calculated by subtracting the viscosity value immediately after preparation from the viscosity value measured after storing each oral composition at 55°C for 6 days. DETAILED DESCRIPTION OF THE INVENTION

[0009] Each embodiment of the present disclosure will be described in more detail below. The present disclosure preferably includes oral compositions, particularly oral compositions containing a thickener, aluminum lactate, and silica, but is not limited thereto. The present disclosure includes all of the compositions disclosed herein and recognizable by a person skilled in the art.

[0010] The oral composition encompassed by the present disclosure contains hydroxyapatite particles in addition to a thickener, aluminum lactate, and silica. Note that this oral composition may be referred to herein as the "oral composition of the present disclosure."

[0011] Hydroxyapatite particles may be those known in the field of oral compositions. Hydroxyapatite particles prepared by known methods or methods easily conceivable from known methods may also be used. Furthermore, commercially available hydroxyapatite may be purchased and used. For example, hydroxyapatite may be purchased and used from Tomita Pharmaceutical Co., Ltd.

[0012] The median diameter (d50) of the hydroxyapatite particles is not particularly limited, but is preferably 5 μm or less, more preferably 4.5 μm or less. The lower limit of the median diameter is not particularly limited, but examples include 1 μm or more, 2 μm or more, or 3 μm or more. More specifically, it is 1 to 5 μm. The median diameter is a value measured by a laser diffraction / scattering method. More specifically, it is a value measured by dry particle size distribution measurement using a laser diffraction particle size distribution analyzer.

[0013] The hydroxyapatite particles can be prepared, for example, by a method for producing hydroxyapatite particles, which includes a step of mixing an aqueous solution of an alkali phosphate having a pH of 4 or more and less than 7 with a calcium hydroxide slurry and reacting them at 35 to 85°C.

[0014] The alkali phosphate salt is not particularly limited and includes hydrates and anhydrates. Examples of the alkali phosphate salt include sodium dihydrogen phosphate, disodium hydrogen phosphate, trisodium phosphate, tetrasodium pyrophosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, tripotassium phosphate, etc., preferably sodium phosphate salts such as sodium dihydrogen phosphate, disodium hydrogen phosphate, trisodium phosphate, etc., more preferably sodium dihydrogen phosphate.

[0015] The concentration of the alkali phosphate in the aqueous alkali phosphate solution is not particularly limited and is, for example, 3 to 50% by mass, preferably 3 to 30% by mass, more preferably 5 to 20% by mass, and even more preferably 7 to 15% by mass.

[0016] The pH of the aqueous solution of alkali phosphate is preferably 4 or more and less than 7. The pH is more preferably 5 to 6.5. As will be described later, when the pH of the aqueous solution of alkali phosphate is relatively low (for example, when the pH is 4 or more and less than 5), an anhydride is used as the alkali phosphate, and the reaction temperature is set to a relatively high temperature, for example, 65 to 85°C, preferably 70 to 85°C. It is more preferable to set the temperature at 75 to 85°C.

[0017] The calcium hydroxide slurry has oxalic acid reactivity, and the calcium hydroxide slurry is preferably a slurry of calcium hydroxide having a specific reactivity with oxalic acid.

[0018] The reactivity towards oxalic acid can be expressed, for example, by the following definition: Oxalic acid reactivity: 40 g of 0.5 mol / L oxalic acid aqueous solution kept at 25±1°C was added all at once to 50 g of calcium hydroxide slurry prepared to a concentration of 5% by mass and kept at 25±1°C, and the time (minutes) until the pH reached 7.0 after addition.

[0019] The specific reactivity to oxalic acid, as defined above, is preferably 1 to 40 minutes, more preferably 5 to 30 minutes, and even more preferably 10 to 20 minutes.

[0020] The BET specific surface area of the calcium hydroxide slurry is preferably 5 m 2 / g or more, more preferably 6m 2 The upper limit of the BET specific surface area is not particularly limited, but is, for example, 20 m 2 / g, 15m 2 / g, 10m 2 / g.

[0021] A calcium hydroxide slurry having high oxalic acid reactivity (e.g., reactivity with the specific oxalic acid described above) can typically be obtained by grinding a calcium hydroxide slurry. The grinding treatment can further increase the oxalic acid reactivity (shorten the time defined above). The grinding treatment is carried out, for example, using a bead mill. The conditions for the grinding treatment are not particularly limited, and can be, for example, the conditions according to the method described in JP 2017-036176 A.

[0022] Calcium hydroxide slurry can be prepared, for example, by reacting water with quicklime (calcium oxide) obtained by calcining limestone. For example, limestone is calcined in a kiln at about 1000°C to produce quicklime, and about 10 times the amount of hot water is added to the quicklime and stirred for 30 minutes to prepare calcium hydroxide slurry.

[0023] The solid content concentration of the calcium hydroxide slurry is not particularly limited, but is, for example, 1 to 30 mass %, preferably 3 to 20 mass %, more preferably 5 to 15 mass %, and even more preferably 6 to 12 mass %.

[0024] The ratio of the amount of the aqueous alkali phosphate solution to the amount of the calcium hydroxide slurry is not particularly limited as long as it is a ratio that allows the production of hydroxyapatite particles. The ratio is preferably adjusted so that the Ca / P molar ratio is 0.3 to 0.7, more preferably 0.4 to 0.6, and even more preferably 0.45 to 0.55.

[0025] The manner in which the aqueous alkali phosphate solution and the calcium hydroxide slurry are mixed is not particularly limited. Examples include an embodiment in which the calcium hydroxide slurry is added to a reaction vessel containing the aqueous alkali phosphate solution (Embodiment 1), an embodiment in which the aqueous alkali phosphate solution is added to a reaction vessel containing the calcium hydroxide slurry (Embodiment 2), and an embodiment in which the aqueous alkali phosphate solution and the calcium hydroxide slurry are added to the reaction vessel simultaneously (Embodiment 3). Among these, Embodiment 1 is preferred. During the addition to the reaction vessel, the liquid in the reaction vessel is usually stirred.

[0026] The addition to the reaction vessel is desirably carried out over a certain period of time, for example, 10 to 90 minutes, preferably 20 to 60 minutes, and more preferably 20 to 40 minutes.

[0027] The reaction is usually carried out under stirring. The reaction temperature is 35 to 85°C. The reaction temperature is preferably 40 to 75°C, more preferably 45 to 70°C, even more preferably 50 to 70°C, and even more preferably 55 to 65°C. When the pH of the aqueous alkali phosphate solution is relatively low (for example, pH 4 or higher but less than 5), the reaction temperature is relatively high, for example, 65 to 85°C, preferably 70 to 85°C, and more preferably 75 to 85°C. The reaction time (the time starting from when the aqueous alkali phosphate solution and the calcium hydroxide slurry are completely mixed; in the above-mentioned embodiments 1 to 3, the time starting from when the addition of the aqueous alkali phosphate solution and the calcium hydroxide slurry is completed) is, for example, 10 to 180 minutes, preferably 20 to 120 minutes, more preferably 40 to 90 minutes, and even more preferably 50 to 70 minutes.

[0028] The hydroxyapatite particles produced by the above steps may be subjected to a purification treatment, such as filtration or washing, if necessary. Furthermore, the particles may be subjected to a drying treatment if necessary.

[0029] The hydroxyapatite particles can be contained in the oral composition in an amount of, for example, about 1 to 10% by mass. The upper or lower limit of this content range may be, for example, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, or 9.5% by mass. For example, the range is more preferably 2 to 8% by mass or 3 to 7% by mass.

[0030] Furthermore, aluminum lactate is preferably contained in the oral composition of the present disclosure in an amount of 0.05 to 3% by mass. The upper or lower limit of this range may be, for example, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, or 2.9% by mass. For example, the range may be 0.1 to 2.7% by mass or 0.2 to 2.5% by mass.

[0031] Furthermore, although not particularly limited, the mass ratio of hydroxyapatite particles to aluminum lactate contained in the oral composition is preferably about 0.2 to 0.6 parts aluminum lactate to 1 part hydroxyapatite particles. The upper or lower limit of this range may be 0.25, 0.3, 0.35, 4, 0.45, 0.5, or 0.55, and for example, about 0.25 to 0.55 or 0.3 to 0.5 is more preferable.

[0032] The thickener contained in the oral composition of the present disclosure may be any known thickener used in the field of oral compositions, such as alginic acid or its salt, hydroxyalkyl cellulose, carboxyalkyl cellulose or its salt, xanthan gum, gellan gum, tragacanth gum, karaya gum, gum arabic, carrageenan, dextrin, polyvinyl alcohol, polyvinylpyrrolidone, thickening silica, Veegum, O-[2-hydroxy-3-(trimethylammonio)propyl]hydroxyethyl cellulose chloride, polyacrylic acid or its salt, agar, etc.

[0033] Among these, alginic acid or a salt thereof, hydroxyalkyl cellulose, carboxyalkyl cellulose or a salt thereof, xanthan gum, and carrageenan are preferred.

[0034] As the salt of alginic acid, alkali metal salts of alginic acid are preferred, more specifically potassium salt and sodium salt, with sodium alginate being particularly preferred.

[0035] The alkyl of the hydroxyalkyl cellulose has 1 to 4 carbon atoms (1, 2, 3, or Preferred is alkyl 4).Specific preferred examples of hydroxyalkyl cellulose include hydroxyethyl cellulose, hydroxypropyl cellulose, and hydroxypropylmethyl cellulose.

[0036] The alkyl of the carboxyalkyl cellulose is preferably an alkyl having 1 to 4 carbon atoms (1, 2, 3, or 4). Specific examples of preferred hydroxyalkyl cellulose include carboxymethyl cellulose and carboxymethyl ethyl cellulose. Furthermore, the salt of the carboxyalkyl cellulose is preferably an alkali metal salt, more specifically, a potassium salt or a sodium salt.

[0037] Preferred examples of the salt of polyacrylic acid include sodium salt and potassium salt.

[0038] The thickener may be used alone or in combination of two or more. The oral composition may contain, for example, about 0.5 to 5% by mass of the thickener, with the upper or lower limit of this range being, for example, 1, 1.5, 2, 2.5, 3, 3.5, 4, or 4.5% by mass. For example, the range may be 1 to 3% by mass or 1 to 2.5% by mass.

[0039] The silica contained in the oral composition of the present disclosure may be any known silica used in the field of oral compositions. For example, precipitated silica may be used. Alternatively, polishing silica may be used. Although not particularly limited, the silica preferably has an average particle size of 2 to 20 μm. The average particle size is measured by laser diffraction / scattering. The silica preferably has a pH (5 aq. sol.) of, for example, about 5.5 to 7.5 or about 6 to 7. The pH (5 aq. sol.) refers to the pH when 5 g of silica is dispersed in 95 mL of purified water. The silica preferably has an oil absorption (cc / 100 g) of, for example, about 10 to 500 or about 20 to 400. The silica may be contained in the oral composition in an amount of, for example, about 1 to 30% by mass. The upper or lower limit of the content range may be, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29% by mass. For example, the range is more preferably 2 to 25% by mass or 3 to 20% by mass.

[0040] The oral composition of the present disclosure does not undergo a significant increase in viscosity even when stored at relatively high temperatures (e.g., about 40 to 60°C). In particular, when stored at 55°C for 6 days, the difference in viscosity (Pa s) between before and after storage is preferably 300 or less in absolute value, and more preferably 250 or less, 200 or less, 150 or less, or 100 or less in absolute value.

[0041] In this specification, the viscosity of the composition is a value measured using a Brookfield type viscometer (manufactured by Brookfield, spindle TF, rotation speed: 10 rpm / minute) after the composition has been kept at 30°C for 30 minutes in a thermostatic bath to bring the temperature to 30°C.

[0042] The oral composition of the present disclosure preferably has a viscosity of 400 Pa·s or less at 30°C, regardless of the time since preparation or storage conditions (particularly storage temperature). In other words, the oral composition of the present disclosure preferably has a viscosity of 400 Pa·s or less at 30°C, whether immediately after preparation or after storage at a relatively high temperature. The viscosity may be, for example, 390, 380, 370, 360, 350, 340, 330, 320, 310, 300, 290, 280, 270, 260, or 250 Pa·s or less. The lower limit of the viscosity is not particularly limited, but examples include approximately 10, 20, 30, 40, 50, or 60 Pa·s.

[0043] The oral composition of the present disclosure may further contain other components that can be incorporated into oral compositions, either alone or in combination of two or more, as long as the effects are not impaired.

[0044] For example, the surfactant may be a nonionic surfactant, an anionic surfactant, or an amphoteric surfactant. Specific examples of nonionic surfactants include sugar fatty acid esters such as sucrose fatty acid esters, maltose fatty acid esters, and lactose fatty acid esters; fatty acid alkanolamides; sorbitan fatty acid esters; fatty acid monoglycerides; polyoxyethylene alkyl ethers having a polyoxyethylene addition coefficient of 8 to 10 and an alkyl group having 13 to 15 carbon atoms; polyoxyethylene alkylphenyl ethers having a polyoxyethylene addition coefficient of 10 to 18 and an alkyl group having 9 carbon atoms; diethyl sebacate; polyoxyethylene hydrogenated castor oil; and fatty acid polyoxyethylene sorbitan. Examples of anionic surfactants include sulfate ester salts such as sodium lauryl sulfate and polyoxyethylene lauryl ether sodium sulfate; sulfosuccinates such as sodium lauryl sulfosuccinate and polyoxyethylene lauryl ether sodium sulfosuccinate; acylamino acid salts such as sodium cocoyl sarcosinate and sodium lauroyl methyl alanine; and sodium cocoyl methyl taurate. Examples of zwitterionic surfactants include acetate betaine surfactants such as lauryl dimethylaminoacetate betaine and coconut oil fatty acid amidopropyl dimethylaminoacetate betaine; imidazoline surfactants such as N-cocoyl-N-carboxymethyl-N-hydroxyethylethylenediamine sodium; and amino acid surfactants such as N-lauryldiaminoethylglycine. These surfactants can be used alone or in combination of two or more. The amount of surfactant used is usually 0.1 to 5% by mass based on the total amount of the composition.

[0045] Sweeteners such as saccharin sodium, acesulfame potassium, stevioside, neohesperidyl dihydrochalcone, perillartine, thaumatin, aspartyl phenylalanyl methyl ester, and p-methoxycinnamic aldehyde may also be added. These may be used alone or in combination of two or more. These may be added in an amount of 0.01 to 1% by mass based on the total amount of the composition.

[0046] Furthermore, sorbitol, glycerin, polypropylene glycol, xylitol, maltitol, lactite, polyoxyethylene glycol, etc. may be blended alone or in combination of two or more kinds as a wetting agent.

[0047] As preservatives, parabens such as methylparaben, ethylparaben, propylparaben, butylparaben, sodium benzoate, phenoxyethanol, alkyldiaminoethylglycine hydrochloride, etc. can be blended alone or in combination of two or more kinds.

[0048] As coloring agents, legal pigments such as Blue No. 1, Yellow No. 4, Red No. 202, Green No. 3, mineral pigments such as ultramarine, enhanced ultramarine, and Prussian blue, titanium oxide, etc. may be used alone or in combination of two or more.

[0049] The pH adjuster may be citric acid, phosphoric acid, malic acid, pyrophosphoric acid, lactic acid, tartaric acid, glycerophosphoric acid, acetic acid, nitric acid, or chemically acceptable salts thereof, or sodium hydroxide. These may be added alone or in combination of two or more so that the pH of the composition is in the range of 4 to 8, preferably 5 to 7. The amount of pH adjuster added is, for example, 0.01 to 2% by weight.

[0050] A bactericide may be blended as a medicinal ingredient. For example, cationic bactericides such as cetylpyridinium chloride, benzalkonium chloride, benzethonium chloride, chlorhexidine hydrochloride, and chlorhexidine gluconate, amphoteric bactericides such as dodecyldiaminoethylglycine, trichlorhexidine, and the like, may be blended as a medicinal ingredient. Examples of suitable antiseptics include nonionic antiseptics such as san and isopropylmethylphenol, and hinokitiol. Furthermore, medicinal ingredients other than antiseptics can also be added. For example, potassium nitrate, vitamin E compounds such as dl-α-tocopherol acetate, tocopherol succinate, or tocopherol nicotinate, and sodium fluoride may be added. The medicinal ingredients can be added alone or in combination of two or more. Potassium nitrate is a medicinal ingredient for preventing dentin hypersensitivity, making it particularly preferable to further add to the oral composition of the present disclosure. When potassium nitrate is added, it can be contained in the oral composition at, for example, about 1 to 10% by mass. The upper or lower limit of the content range may be, for example, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, or 9.5% by mass. For example, the range is more preferably 2 to 8% by mass or 3 to 7% by mass.

[0051] Furthermore, as a base, for example, alcohols, silicone, apatite, white petrolatum, paraffin, liquid paraffin, microcrystalline wax, squalane, plastibase, etc. can be added alone or in combination of two or more kinds.

[0052] The above descriptions of optional components are merely examples and do not limit the optional components that can be used.

[0053] In this specification, the term "comprising" includes "consisting essentially of" and "consisting of." Furthermore, the present disclosure encompasses all arbitrary combinations of the constituent elements described in this specification.

[0054] Furthermore, the various characteristics (properties, structures, functions, etc.) described in each embodiment of the present disclosure above may be combined in any way to specify the subject matter encompassed by the present disclosure, i.e., the present disclosure encompasses all subject matter consisting of any combination of the combinable characteristics described herein. [Example]

[0055] The subject matter of the present disclosure will be described in more detail below based on examples, but the subject matter of the present disclosure is not limited to these examples.

[0056] Manufacturing Example 1: Preparation of hydroxyapatite particles A 10.7% by mass aqueous solution of sodium dihydrogen phosphate dihydrate and a 8.6% by mass solids grinding-treated calcium hydroxide slurry (BET specific surface area: 6.7 m) were mixed so that the Ca / P molar ratio was 0.5. 2 / g Oxalic acid reactivity: 15 minutes 30 seconds (JP Patent Publication No. 2017-036176) was prepared. An aqueous solution of sodium dihydrogen phosphate dihydrate was placed in a stainless steel beaker and heated to 60°C while stirring, and maintained at this temperature until the stirring stopped. A 10% aqueous solution of NaOH was added to adjust the pH to 5.5. The calcium hydroxide slurry was then added over 30 minutes. After the addition was completed, the mixture was stirred for another hour, then filtered, washed with water, and dried at 80°C to obtain hydroxyapatite particles (powder).

[0057] Study example: Study of viscosity change of oral composition due to aluminum lactate Each oral composition was prepared by mixing the components shown in Table 1. Caustic soda was also added to the composition containing aluminum lactate to adjust the pH to around 7. The numerical values of each component shown in Table 1 indicate mass %. In Table 1, "Production Example 1 HAp" indicates hydroxyapatite particles obtained in the same manner as in Production Example 1, and "Commercially available HAp" indicates commercially available hydroxyapatite particles (manufactured by Tomita Pharmaceutical Co., Ltd.). In Table 1, "silica" was one of five commercially available types of silica (referred to as silica a, b, c, d, and e), and "hydroxyapatite" was one of the five commercially available types of silica. As the "hydroxyapatite particles," either the HAp of Production Example 1 or commercially available HAp was used, or no HAp was used. Each oral composition was prepared by combining these "silica" and "hydroxyapatite particles" (see Tables 2a, 2b, and 2c). The characteristics of the five types of silica used are summarized in Table 3.

[0058] The viscosity of each oral composition was measured immediately after preparation. Furthermore, 60 mL or more of each composition was filled into a colorless, transparent glass container (manufactured by Kakuyo Glass Co., Ltd.) with a full capacity of 83.5 mL and a body diameter of 45.5 mm. The viscosity was measured immediately after filling and after storage at 55°C in a dark place for 6 days. The viscosity measurements were performed using a B-type viscometer (manufactured by Brookfield, spindle TF, rotation speed: 10 rpm / min) after incubating each oral composition in a constant temperature bath at 30°C for 30 minutes. The viscosity immediately after preparation is shown in Table 2a, and the viscosity after storage at 55°C for 6 days is shown in Table 2b. Furthermore, the viscosity values calculated by subtracting the viscosity values immediately after preparation from the viscosity values after storage are shown in Table 2c. The results of Table 2c are graphed and shown in Figure 1.

[0059] [Table 1]

[0060] [Table 2a]

[0061] [Table 2b]

[0062] [Table 2c]

[0063] [Table 3]

[0064] In addition, oral compositions were prepared and stored in the same manner as above, except that commercially available HAp was used as the hydroxyapatite particles, silica c, silica d, or silica e was used as the commercially available silica, the aluminum lactate content was 0.2% by mass, the 48% caustic soda content was 0.1% by mass, and the storage conditions were room temperature for 6 days. The viscosity was then measured. The viscosity immediately after preparation is shown in Table 4a, and the viscosity after 6 days of storage at room temperature is shown in Table 4b. Furthermore, the viscosity values calculated by subtracting the viscosity values immediately after preparation from the viscosity values after storage are shown in Table 4c.

[0065] [Table 4a]

[0066] [Table 4b]

[0067] [Table 4c]

Claims

1. An oral composition comprising a thickener, aluminum lactate, silica, and hydroxyapatite particles, the thickener is at least one selected from the group consisting of alginic acid or a salt thereof, hydroxyalkyl cellulose, carboxyalkyl cellulose or a salt thereof, xanthan gum, and carrageenan; 0.5 to 5% by mass of a thickener, 0.05 to 3 mass% aluminum lactate, 1 to 30 mass% of silica, 1 to 10% by mass of hydroxyapatite particles, Contains The silica has an average particle size of 6 to 20 μm and an oil absorption (cc / 100 g) of 90 to 400. Oral compositions (excluding oral compositions containing 0.5 to 5% by mass of carboxymethylcellulose or a salt thereof).

2. 2. The oral composition according to claim 1, which has a viscosity at 30°C of 400 Pa·s or less.

3. 1 to 3% by mass of a thickener, 0.1 to 2.7% by mass of aluminum lactate, 2 to 25% by mass of silica, 2 to 8% by mass of hydroxyapatite particles, Contains The oral composition according to claim 1 or 2.

4. When stored at 55°C for 6 days, the difference in viscosity (Pa·s) before and after storage is 150 or less in absolute value. The oral composition according to any one of claims 1 to 3.

Images